2026-03-14T17:46:14Z https://kanazawa-u.repo.nii.ac.jp/oai

oai:kanazawa-u.repo.nii.ac.jp:00013103 2024-06-20T07:17:02Z 1132:1133:1134

Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine Mabuchi, Hiroshi 389 00019960 00019960 Sakai, Takeshi 20757 Sakai, Yasuyuki 20758 Yoshimura, Akira 20759 Watanabe, Akira 20760 Wakasugi, Takanobu 20761 Koizumi, Junji 20266 20161846 20161846 Takeda, Ryoyu 20762 We studied the effects of the bile acid sequestrant cholestyramine, alone and in combination with the experimental agent compactin (ML-236B), a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on serum levels of lipoproteins in 10 heterozygous patients with familial hypercholesterolemia. After cholestyramine treatment alone for 2 to 16 months, serum total and low-density lipoprotein cholesterol decreased by 20 and 28 per cent, respectively. With the addition of compactin for 12 weeks there was a 39 per cent total decrease in serum cholesterol from the control value - from 356 ± 14 to 217 ± 10 mg per deciliter (9.27 ± 0.36 to 5.64 ± 0.26 nmol per liter [mean ± S.E.M.]; P < 0.001) - and a 53 per cent decrease in low-density lipoprotein cholesterol - from 263 ± 13 to 125 ± 10 mg per deciliter (6.84 ± 0.34 to 3.25 ± 0.26 nmol per liter; P < 0.001). High-density lipoprotein cholesterol, which had increased during cholestyramine treatment, remained at its higher level. No adverse effects were observed. If long-term safety can be demonstrated, the compactin-cholestyramine regimen may prove useful in heterozygous familial hypercholesterolemia. journal article Massachusetts Medical Society 1983-01-01 VoR application/pdf New England Journal of Medicine 11 308 609 613 AA00755156 0028-4793 https://kanazawa-u.repo.nii.ac.jp/record/13103/files/ME-PR-MABUCHI-H-609.pdf http://hdl.handle.net/2297/9917 https://kanazawa-u.repo.nii.ac.jp/records/13103 eng https://doi.org/10.1056/nejm198303173081101